Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
CALDOLOR (IBUPROFEN) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
CALDOLOR
NDA
Get alerts
IBUPROFEN | N022348 | CUMBERLAND PHARMACEUTICALS INC
3 strengths
10 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
10 unique patents, 1 exclusivity by expiration date
All strengths
400MG/4ML (100MG/ML)
800MG/8ML (100MG/ML)
800MG/200ML (4MG/ML)
Active (10)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
Today
8735452
Sep. 30, 2029
8871810
Sep. 30, 2029
9012508
Sep. 14, 2030
9072661
Mar. 16, 2032
9072710
Mar. 16, 2032
9114068
Sep. 30, 2029
9138404
Sep. 30, 2029
9295639
Sep. 30, 2029
9649284
Sep. 30, 2029
11806400
Mar. 16, 2032
NPP
May. 11, 2026
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 400MG/4ML (100MG/ML)
0 patents
1 exclusivity
▴
SOLUTION;INTRAVENOUS | Approved: Jun 11, 2009
Exclusivities (1)
Code
Date
Status
NPP
May 11, 2026
Expired
#002 — 800MG/8ML (100MG/ML)
RLD
8 patents
1 exclusivity
▾
SOLUTION;INTRAVENOUS | Approved: Jun 11, 2009
#003 — 800MG/200ML (4MG/ML)
RLD
6 patents
1 exclusivity
▾
SOLUTION;INTRAVENOUS | Approved: Jan 25, 2019